Floatz logo

cd19/bcma-targeted car-t cells

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) cohort.

Asset / SponsorPhaseRating
Fludarabine
Kite, A Gilead Company
Phase 1CCC
Cyclophosphamide
Kite, A Gilead Company
Phase 1CCC
Universal Cd19 Car-Γδt Cell
Tongji Hospital
Phase 1CC
Bcma Targeted Car T-Cells
Tongji Hospital
Early Phase 1C

Same molecule, other indications

cd19/bcma-targeted car-t cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →
B Cell LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →